Results 101 to 110 of about 36,124 (280)

Effect of DNA input on analytical and clinical parameters of a circulating tumor DNA assay for comprehensive genomic profiling

Journal of Laboratory Medicine
Circulating tumor DNA (ctDNA) assays play an increasingly important role in cancer management. A new version of TruSight Oncology 500 (TSO500) ctDNA, v2, was recently released, and the recommended DNA input was decreased to 20 ng from 30 ng in the prior ...
Lee Cheonghwa, Ha Changhee, Kim Young-gon, Kim Jong-Won   +3 more
doaj   +1 more source

The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST [PDF]

Clinical Cancer Research
Abstract Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates our recently proposed ctDNA-RECIST.
Mette M. Steiniche, Sidsel C. Lindgaard, Inna M. Chen, Julia S. Johansen, Rikke F. Andersen, Torben F. Hansen, Lars H. Jensen, Louise S. Rasmussen, Malene W. Johansen, Morten Ladekarl, Anders K.M. Jakobsen, Karen-Lise G. Spindler   +11 more
openaire   +3 more sources

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas

Journal of Clinical Laboratory Analysis, EarlyView.
Laboratory tests must exhibit robustness to common sources of test variability, particularly for tests with the potential to inform treatment decisions. This study presents data that shows that a phased variant enrichment and detection sequencing (PhasED‐Seq)‐based circulating tumor DNA minimal residual disease (ctDNA‐MRD) test is robust, with results ...
Nina Klimova, Alanna Roff, Justine McCutcheon, Alex Aheimer, Sandra L. Close, Richard D. Hockett, Stephanie Meek, Laura Hyland   +7 more
wiley   +1 more source

Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population

Molecular Carcinogenesis, EarlyView.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed malignancy among men and the sixth leading cause of cancer‐related mortality worldwide. Radical prostatectomy remains the standard treatment for localized disease; however, approximately one‐third of patients develop biochemical recurrence within 10 years. Although prostate‐specific
Juliana Ramos Chaves, Rommel Mario Rodriguez Burbano, Amanda de Nazaré Cohen‐Paes, Diego Di Felipe Ávila Alcântara, Ana Paula Borges de Souza, Maria Janete Nahum Gomes, Sérgio Augusto Antunes Ramos, André Salim Khayat   +7 more
wiley   +1 more source

AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. [PDF]

, 2016
BACKGROUND: The single hotspot mutation AKT1 [G49A:E17K] has been described in several cancers, with the highest incidence observed in breast cancer. However, its precise role in disease etiology remains unknown. METHODS: We analyzed more than 600 breast
Anzeneder, Tobias, Beckmann, Georg, Byrne, Annette T, Jeffers, Michael, Köchert, Karl, Pena, Carol, Politz, Oliver, Reischl, Joachim, Rudolph, Marion, Schulz, Anke, Vonk, Richardus   +10 more
core   +1 more source

Molecular Diagnostics in Thyroid Nodules: Current Applications, Clinical Value, and Future Perspective

Med Research, EarlyView.
ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao, Min Ding, Zhixue Min, Yihan Dong, Xuanye Cao, Qiang Lu, Cong Chen, Yahui Wu, Xin Guo, Zhen Wu, Jing Xie, Dan Xu, Haizhen Chen, Rongli Xie, Jian Fei   +14 more
wiley   +1 more source

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. [PDF]

, 2019
PurposeMolecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular carcinoma (HCC) given the challenge of obtaining liver tissue biopsies.Experimental designWe ...
Abdel-Wahab, Reham, Amin, Hesham M, Banks, Kimberly C, Bocobo, Andrea G, George, Bhawana, Haque, Abedul, Hassan, Manal M, Ikeda, Sadakatsu, Kaseb, Ahmed O, Kelley, Robin K, Kurzrock, Razelle, Lanman, Richard B, Lim, Kian H, Meric-Bernstam, Funda, Mills-Shaw, Kenna R, Morris, Jeffrey, Pestana, Roberto Carmagnani, Qiao, Wei, Raghav, Kanwal PS, Rashid, Asif, Sen, Shiraj, Sánchez, Nora S, Talasaz, AmirAli, Tan, Benjamin, Uemura, Marc, Wolff, Robert A, Xiao, Lianchun, Yao, James C   +27 more
core   +1 more source

Nanopore Sequencing for HPV in Oropharyngeal Squamous Cell Carcinoma and Benign Tonsil Specimens

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objectives Human papillomavirus (HPV) accounts for the majority of oropharyngeal squamous cell carcinoma (OPSCC) cases in the United States but understanding the prevalence of high‐risk HPV in oropharyngeal tissue remains poor. We evaluated nanopore sequencing, a novel rapid, and long‐read sequencing platform, on OPSCC tissue and tested it in ...
Mikayla G. Hubbard, Guang‐Sheng Lei, Robert Emerson, Danielle Schreiber, Thomas E. Davis, Diane W. Chen   +5 more
wiley   +1 more source

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

BMC Cancer, 2018
Background Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is
Ashleigh C. McEvoy, Lydia Warburton, Zeyad Al-Ogaili, Liesl Celliers, Leslie Calapre, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Melanie Ziman, Elin S. Gray   +10 more
doaj   +1 more source